Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study

References

• Pate CA, Zahran HS, Qin X, et al. Asthma surveillance—United States, 2006–2018. MMWR Surveill Summ. 2021;70(5):1–32. doi: 10.15585/mmwr.ss7005a1.
   PubMed Web of Science ®Google Scholar
• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European respiratory society/American thoracic society guideline. Eur Respir J. 2020;55(1):1900588. doi: 10.1183/13993003.00588-2019.
   PubMed Web of Science ®Google Scholar
• Barry LE, Sweeney J, O’Neill C, et al. The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis. Respir Res. 2017;18(1):129. doi: 10.1186/s12931-017-0614-x.
   PubMed Web of Science ®Google Scholar
• Chastek B, Korrer S, Nagar SP, et al. Economic burden of illness among patients with severe asthma in a managed care setting. J Manag Care Spec Pharm. 2016;22(7):848–861. doi: 10.18553/jmcp.2016.22.7.848.
   PubMedGoogle Scholar
• Settipane RA, Kreindler JL, Chung Y, et al. Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States. Ann Allergy Asthma Immunol. 2019;123(6):564–572. e3. doi: 10.1016/j.anai.2019.08.462.
   PubMed Web of Science ®Google Scholar
• Song HJ, Blake KV, Wilson DL, et al. Medical costs and productivity loss due to mild, moderate, and severe asthma in the United States. J Asthma Allergy. 2020;13:545–555. doi: 10.2147/JAA.S272681.
   PubMed Web of Science ®Google Scholar
• Nurmagambetov TA, Krishnan JA. What will uncontrolled asthma cost in the United States? Am J Respir Crit Care Med. 2019;200(9):1077–1078. doi: 10.1164/rccm.201906-1177ED.
   PubMed Web of Science ®Google Scholar
• Yaghoubi M, Adibi A, Safari A, et al. The projected economic and health burden of uncontrolled asthma in the United States. Am J Respir Crit Care Med. 2019;200(9):1102–1112. doi: 10.1164/rccm.201901-0016OC.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2021. https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf
   Google Scholar
• Dalal AA, Duh MS, Gozalo L, et al. Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma. J Manag Care Spec Pharm. 2016;22(7):833–847. doi: 10.18553/jmcp.2016.22.7.833.
   PubMedGoogle Scholar
• Lefebvre P, Duh MS, Lafeuille M-H, et al. Acute and chronic systemic corticosteroid–related complications in patients with severe asthma. J Allergy Clin Immunol. 2015;136(6):1488–1495. doi: 10.1016/j.jaci.2015.07.046.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Aiello M, Frizzelli A, et al. Oral corticosteroids dependence and biologic drugs in severe asthma: myths or facts? A systematic review of Real-World evidence. Int J Mol Sci. 2021;22(13):7132. doi: 10.3390/ijms22137132.
   PubMed Web of Science ®Google Scholar
• FASENRA (benralizumab) Prescribing information. AstraZeneca Pharmaceuticals LP. Wilmington. 2021.
   Google Scholar
• Carstens D, Maselli DJ, Mu F, et al. Largest real-world effectiveness study of benralizumab for severe eosinophilic asthma: ZEPHYR 2. J Allergy Clin Immunol Pract. 2023;11(7):2150–2161.e4. doi: 10.1016/j.jaip.2023.04.029.
   PubMed Web of Science ®Google Scholar
• Charles D, Shanley J, Temple SN, et al. Real‐world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta‐analysis. Clin Exp Allergy. 2022;52(5):616–627. doi: 10.1111/cea.14112.
   PubMed Web of Science ®Google Scholar
• Chung Y, Katial R, Mu F, et al. Real-world effectiveness of benralizumab: results from the ZEPHYR 1 study. Ann Allergy Asthma Immunol. 2022;128(6):669–676. e6. doi: 10.1016/j.anai.2022.02.017.
   PubMed Web of Science ®Google Scholar
• Kayser MZ, Drick N, Milger K, et al. Real-world multicenter experience with mepolizumab and benralizumab in the treatment of uncontrolled severe eosinophilic asthma over 12 months. J Asthma Allergy. 2021;14:863–871. doi: 10.2147/JAA.S319572.
   PubMed Web of Science ®Google Scholar
• Menzella F, Fontana M, Galeone C, et al. Real world effectiveness of benralizumab on respiratory function and asthma control. Multidiscip Respir Med. 2021;16(1):785. doi: 10.4081/mrm.2021.785.
   PubMed Web of Science ®Google Scholar
• XOLAIR (omalizumab) Prescribing information. Genentech, South San Francisco. 2021.
   Google Scholar
• NUCALA (mepolizumab) Prescribing information. GlaxoSmithKline LLC, Philadelphia. 2022.
   Google Scholar
• Agency for Healthcare Research and Quality (AHRQ). HCUPnet - Healthcare Cost and Utilization Project. Rockville, MD. 2022. https://hcupnet.ahrq.gov/
   Google Scholar
• Reibman J, Tan L, Ambrose C, et al. Clinical and economic burden of severe asthma among US patients treated with biologic therapies. Ann Allergy Asthma Immunol. 2021;127(3):318–325. e2. doi: 10.1016/j.anai.2021.03.015.
   PubMed Web of Science ®Google Scholar
• Kerkhof M, Tran TN, Soriano JB, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax. 2018;73(2):116–124. doi: 10.1136/thoraxjnl-2017-210531.
   PubMed Web of Science ®Google Scholar
• Pfeffer PE, Ali N, Murray R, et al. Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both. Allergy. 2023;78(7):1934–1948. doi: 10.1111/all.15711.
   PubMed Web of Science ®Google Scholar
• Nguyen HV, Nadkarni NV, Sankari U, et al. Association between asthma control and asthma cost: results from a longitudinal study in a primary care setting. Respirology. 2017;22(3):454–459. doi: 10.1111/resp.12930.
   PubMed Web of Science ®Google Scholar
• López-Tiro J, Contreras-Contreras A, Rodríguez-Arellano ME, et al. Economic burden of severe asthma treatment: a real-life study. World Allergy Organ J. 2022;15(7):100662. doi: 10.1016/j.waojou.2022.100662.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Hoyte FL, Price DB, et al. Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with benralizumab. Adv Ther. 2022;39(5):2065–2084. doi: 10.1007/s12325-022-02098-1.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow AN, McBrien C, Unni B, et al. Real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE study. J Asthma Allergy. 2022;15:63–78. doi: 10.2147/JAA.S328653.
   PubMed Web of Science ®Google Scholar
• Numata T, Araya J, Miyagawa H, et al. Effectiveness of switching biologics for severe asthma patients in Japan: a single-center retrospective study. J Asthma Allergy. 2021;14:609–618. doi: 10.2147/JAA.S311975.
   PubMed Web of Science ®Google Scholar
• Panettieri RA, Jr Ledford DK, Chipps BE, et al. Biologic use and outcomes among adults with severe asthma treated by United States subspecialists. Ann Allergy Asthma Immunol. 2022;129(4):467–474.e3. doi: 10.1016/j.anai.2022.06.012.
   PubMed Web of Science ®Google Scholar
• Fernández AG-B, Gallardo JFM, Romero JD, et al. Effectiveness of switching to benralizumab in severe refractory eosinophilic asthma. J Asthma Allergy. 2022;15:727.
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Burhan H, Menzies-Gow A, et al. Benralizumab effectiveness in severe asthma is independent of previous biologic use. J Allergy Clin Immunol Prac. 2022;10(6):1534–1544.e4. doi: 10.1016/j.jaip.2022.02.014.
   PubMed Web of Science ®Google Scholar
• Martínez-Moragón E, García-Moguel I, Nuevo J, et al. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study). BMC Pulm Med. 2021;21(1):417. doi: 10.1186/s12890-021-01785-z.
   PubMed Web of Science ®Google Scholar